Trial Profile
An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Balixafortide (Primary) ; Eribulin
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms FORTRESS
- Sponsors Polyphor; Spexis
- 07 Jul 2022 According to a Spexis media release, Status changed from active, no longer recruiting to discontinued.
- 25 Aug 2021 This trial has been Discontinued in Belgium and Germany,according to European Clinical Trials Database record.
- 21 Aug 2021 This trial has been Discontinued in Czechia,according to European Clinical Trials Database record.